Ibogaine Research Database

692 research records indexed from PubMed. Plain-language summaries where available.

Of these, 52 are human clinical studies (trials, observational studies, or case reports), 398 are preclinical (animal or lab) studies, and 112 are reviews or meta-analyses summarizing other researchers’ data. A record appearing here does not by itself mean ibogaine is proven effective for a given condition — see each condition page’s evidence breakdown for what’s actually established.

Compare evidence by condition →

All Studies (692)Depression (56)PTSD (24)Alcohol Addiction (20)Heroin Addiction (16)Opioid Addiction (15)Cocaine Addiction (15)Anxiety (13)Methamphetamine Addiction (12)Traumatic Brain Injury (2)

All Studies(692 of 692)

Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials.

Bakouni, Sharafi, Bahremand· Drug and alcohol dependence· 2023· PMID: 37979478
Meta-Analysis

This meta-analysis (PROSPERO-ID: CRD42022362962), pooled effect estimates of outcomes, from placebo-controlled randomized clinical trials (RCTs) examining bupropion efficacy and safety for amphetamine-type stimulant use disorder (ATSUD) treatment. Electronic databases were search...

Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.

Heinsbroek, Giannotti, Bonilla· Psychedelic medicine (New Rochelle, N.Y.)· 2023· PMID: 37360328
Preclinical (Lab)

The potential use of psychedelic drugs as therapeutics for neuropsychiatric disorders has been limited by their hallucinogenic properties. To overcome this limitation, we developed and characterized tabernanthalog (TBG), a novel analogue of the indole alkaloids ibogaine and 5-met...

Motivations for Cannabis Use in Individuals with Social Anxiety Disorder (SAD).

Elsaid, Wang, Kloiber· Brain sciences· 2023· PMID: 38137146
Preclinical (Lab)

Social anxiety disorder (SAD) is a debilitating psychiatric condition. Consequently, it is common for those affected to resort to cannabis to cope with their symptoms. The primary objective of this study was to understand the differences between motivations for cannabis use in ad...

Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.

Sharma, Batchelor, Sin· Journal of psychoactive drugs· 2023· PMID: 36933948
Systematic Review

Renewed interest in psychedelic substances in the 21st century has seen the exploration of psychedelic treatments for various psychiatric disorders including substance use disorder (SUD). This review aimed to assess the effectiveness of psychedelic treatments for people with SUD ...

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.

Davis, Xin, Sepeda· The American journal of drug and alcohol abuse· 2023· PMID: 37734158
Observational Study

Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these treatments are effective for Veteran populations.Objectives: Here, we examine the effectiveness of psychedelic-assisted therapy among tr...

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.

Mastinu, Anyanwu, Carone· International journal of molecular sciences· 2023· PMID: 36674849
Review

The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addition, difficulties in finding new drugs have led pharmacologists to review and re-evaluate some past molecules, including psychedelics...

Neuroimaging in psychedelic drug development: past, present, and future.

Wall, Harding, Zafar· Molecular psychiatry· 2023· PMID: 37759038
Review

Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, addiction, post-traumatic stress disorder, and potentially others. 'Classic' serotonergic psychedelics, such as psilocybin and lysergic ...

Insula deep rTMS and varenicline for smoking cessation: A randomized control trial study protocol.

Ibrahim, Malik, Barr et al.· Front Pharmacol· 2022· PMID: 36160428
Preclinical (Lab)

Background: Current approved therapies for smoking cessation have modest long-term effects for abstinence. The insular cortex has been identified by preclinical and clinical studies as a critical target for addiction treatment. Insula functions can be modulated non-invasively usi...

The substrate import mechanism of the human serotonin transporter.

Chan, Selvam, Young et al.· Biophys J· 2022· PMID: 35114149
Unclassified

The serotonin transporter (SERT) initiates the reuptake of extracellular serotonin in the synapse to terminate neurotransmission. The cryogenic electron microscopy structures of SERT bound to ibogaine and the physiological substrate serotonin resolved in different states have pro...

Recycling Upstream Redox Enzymes Expands the Regioselectivity of Cycloaddition in Pseudo-Aspidosperma Alkaloid Biosynthesis.

Kamileen, DeMars, Hong et al.· J Am Chem Soc· 2022· PMID: 36240425
Preclinical (Lab)

Nature uses cycloaddition reactions to generate complex natural product scaffolds. Dehydrosecodine is a highly reactive biosynthetic intermediate that undergoes cycloaddition to generate several alkaloid scaffolds that are the precursors to pharmacologically important compounds s...

The potential of psychedelic medicine - A personal account.

Smith· J Neurol Sci· 2022· PMID: 34998238
Preclinical (Animal)

In 1965, I was training in clinical toxicology in the pharmacology department of the University of California San Francisco (UCSF) and living in the Haight Ashbury. I studied various psychedelics, including LSD, mescaline, and ibogaine, in human and animal models. The psychedelic...

Ibogaine microdosing in a patient with bipolar depression: a case report.

Fernandes-Nascimento, Viana-Ferreira, Chaves et al.· Braz J Psychiatry· 2022· PMID: 35896190
Preclinical (Lab)

United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.

Barnett, Parker, Weleff· Int J Drug Policy· 2022· PMID: 34624734
Clinical Trial

Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistently demonstrated promising findings for psychedelic-assisted therapies in the treatment of various mental health conditions and addict...

Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones.

Sutton, Williams, Homsi et al.· Front Cell Neurosci· 2022· PMID: 35614973
Preclinical (Lab)

Mutations in the dopamine transporter gene (SLC6A3) have been implicated in many human diseases. Among these is the infantile parkinsonism-dystonia known as Dopamine Transporter Deficiency Syndrome (DTDS). Afflicted individuals have minimal to no functional dopamine transporter p...

Voacamine is a novel inhibitor of EGFR exerting oncogenic activity against colorectal cancer through the mitochondrial pathway.

Chen, Yang, Zuo et al.· Pharmacol Res· 2022· PMID: 36029932
Preclinical (Animal)

Colorectal cancer (CRC), among the most aggressive and prevailing neoplasms, is primarily treated with chemotherapy. Voacamine (VOA), a novel bisindole natural product, possesses a variety of conspicuous pharmacological activities. Within the current research, we evaluated in vit...

Antiproliferative and Microtubule-stabilizing Activities of Two Iboga-vobasine Bisindoles Alkaloids from Tabernaemontana corymbosa in Colorectal Adenocarcinoma HT-29 Cells.

Tan, Sim, Lim et al.· Planta Med· 2022· PMID: 35100653
Unclassified

Two iboga-vobasine bisindoles, 16'-decarbomethoxyvoacamine (1: ) and its 19,20-dihydro derivative, 16'-decarbomethoxydihydrovoacamine (2: ) from Tabernaemontana corymbosa exhibited potent cytotoxicity against the human colorectal adenocarcinoma HT-29 cells in our previous studies...

Antimycobacterial Activity of Alkaloids and Extracts from Tabernaemontana alba and T. arborea.

Guzmán-Gutiérrez, Silva-Miranda, Krengel et al.· Planta Med· 2022· PMID: 32392600
Preclinical (Animal)

Tuberculosis is the main cause of death from a single infectious agent. Globally, according to the World Health Organization, in 2018, there were an estimated 1.2 million tuberculosis deaths. Moreover, there is a continuous appearance of drug-resistant strains. Thus, development ...

A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells.

Pellegrini, Multari, Gallo et al.· Toxicol Appl Pharmacol· 2022· PMID: 34856211
Unclassified

Most women with ovarian cancer are treated with chemotherapy before or after surgery. Unfortunately, chemotherapy treatment can cause negative side effects and the onset of multidrug resistance (MDR). The aim of this study is to evaluate the chemosensitizing effect of a natural c...

Reply to Knuijver et al. on the 'Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study'.

Luz, Mash· Addiction· 2022· PMID: 34542215
Observational Study

Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites.

F Martins, Heydari, Li et al.· Front Pharmacol· 2022· PMID: 35308219
Preclinical (Lab)

The psychedelic alkaloid ibogaine is increasingly used as an oral treatment for substance use disorders, despite being unlicensed in most countries and having reported adverse events. Using wild-type and genetically modified mice, we investigated the impact of mouse (m)Abcb1a/1b ...

Response to Luz & Mash on cardiac toxicity of ibogaine.

Schellekens, Kramers, Knuijver et al.· Addiction· 2022· PMID: 34859515
Unclassified

Neurotoxicology

González-Trujano, Krengel, Reyes-Chilpa et al.· Neurotoxicology· 2022· PMID: 34999156
Preclinical (Animal)

Several Apocynaceae species, most notably Tabernanthe iboga, Voacanga africana and many Tabernaemontana species, produce ibogan-type alkaloids. Although a large amount of information exists about the Tabernaemontana genus, knowledge concerning chemistry and biological activity re...

Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders.

Kargbo· ACS Med Chem Lett· 2022· PMID: 35707155
Preclinical (Lab)

The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Ona, Rocha, Bouso et al.· Psychopharmacology (Berl)· 2022· PMID: 34406452
Systematic Review

Ibogaine is the main alkaloid of the African shrub Tabernanthe iboga. It produces hallucinogenic and psychostimulant effects, but it is currently known for the anti-addictive properties. Despite the potential therapeutic effects, several cases of fatalities and serious adverse ev...

A systematic literature review of clinical trials and therapeutic applications of ibogaine.

Köck, Froelich, Walter et al.· J Subst Abuse Treat· 2022· PMID: 35012793
Systematic Review

Iboga and its primary alkaloids, ibogaine and noribogaine, have been of interest to researchers and practitioners, mainly due to their putative efficacy in treating substance use disorders (SUDs). For many SUDs, still no effective pharmacotherapies exist. Distinct psychoactive an...

Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.

Vorobyeva, Kozlova· Frontiers in pharmacology· 2022· PMID: 35837277
Review

Classical psychedelics represent a family of psychoactive substances with structural similarities to serotonin and affinity for serotonin receptors. A growing number of studies have found that psychedelics can be effective in treating various psychiatric conditions, including pos...

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.

Bozinoff, Tardelli, Rubin-Kahana· Harm reduction journal· 2022· PMID: 36229831
Systematic Review

Given the ongoing opioid crisis, novel interventions to treat severe opioid use disorder (OUD) are urgently needed. Injectable opioid agonist therapy (iOAT) with diacetylmorphine or hydromorphone is effective for the treatment of severe, treatment-refractory OUD, however barriers...

Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.

Knuijver, Schellekens, Belgers· Addiction (Abingdon, England)· 2022· PMID: 33620733
Observational Study

Ibogaine is an indole alkaloid used in rituals of the African Bwiti tribe. It is also used in non-medical settings to treat addiction. However, ibogaine has been linked to several deaths, mainly due to cardiac events called torsades des pointes preceded by QTc prolongation as wel...

Identification of Effective Anticancer G-Quadruplex-Targeting Chemotypes through the Exploration of a High Diversity Library of Natural Compounds.

Platella, Ghirga, Zizza et al.· Pharmaceutics· 2021· PMID: 34683905
Preclinical (Lab)

In the quest for selective G-quadruplex (G4)-targeting chemotypes, natural compounds have been thus far poorly explored, though representing appealing candidates due to the high structural diversity of their scaffolds. In this regard, a unique high diversity in-house library comp...

Rescue of two trafficking-defective variants of the neuronal glycine transporter GlyT2 associated to hyperekplexia.

de la Rocha-Muñoz, Melgarejo, Aragón et al.· Neuropharmacology· 2021· PMID: 33794243
Preclinical (Animal)

Hyperekplexia is a rare sensorimotor syndrome characterized by pathological startle reflex in response to unexpected trivial stimuli for which there is no specific treatment. Neonates suffer from hypertonia and are at high risk of sudden death due to apnea episodes. Mutations in ...

Chemical communications (Cambridge, England)

Gurram, Nanubolu, Menon· Chem Commun (Camb)· 2021· PMID: 33346280
Preclinical (Lab)

The azepinoindole framework present in natural alkaloids such as subincanadine F, ibogaine and catharanthine was formed in a novel acid-promoted cyclization-rearrangement of tryptamine-derived N-sulfonyl enamines. The latter were conveniently prepared via a cesium carbonate media...

Engineering Safer Psychedelics for Treating Addiction.

Peters, Olson· Neuroscience insights· 2021· PMID: 34350400
Preclinical (Lab)

Addiction is best described as a disorder of maladaptive neuroplasticity involving the simultaneous strengthening of reward circuitry that drives compulsive drug seeking and weakening of circuits involved in executive control over harmful behaviors. Psychedelics have shown great ...

ACS omega

González, Fagúndez, Peixoto de Abreu Lima et al.· ACS Omega· 2021· PMID: 34250335
Preclinical (Lab)

Iboga alkaloids are a group of monoterpenoid indole alkaloids with promising and intriguing biological activities. Ibogaine is the representative member of the series and has become widely known as a potent atypical psychedelic with promising effects to treat substance use disord...

EEG Gamma Band Alterations and REM-like Traits Underpin the Acute Effect of the Atypical Psychedelic Ibogaine in the Rat.

González, Cavelli, Castro-Zaballa et al.· ACS Pharmacol Transl Sci· 2021· PMID: 33860181
Preclinical (Lab)

Ibogaine is a psychedelic alkaloid that has attracted large scientific interest because of its antiaddictive properties in observational studies in humans as well as in animal models. Its subjective effect has been described as intense, vivid dream-like experiences occurring whil...

Antioxidants (Basel, Switzerland)

Tatalović, Vidonja Uzelac, Oreščanin Dušić et al.· Antioxidants (Basel)· 2021· PMID: 34829663
Preclinical (Lab)

Ibogaine effects are mediated by cellular receptors, ATP depletion followed by ROS production and antioxidant enzyme activity elevation in a dose and time dependent manner. Since the role of KATP channels and β-adrenoceptors in ROS cellular circuit was established here we explore...

Ibogaine Blocks Cue- and Drug-Induced Reinstatement of Conditioned Place Preference to Ethanol in Male Mice.

Henriques, Anjos-Santos, Rodrigues et al.· Front Pharmacol· 2021· PMID: 34621171
Preclinical (Lab)

Ibogaine is a psychedelic extracted from the plant Tabernanthe iboga Baill. (Apocynaceae), natural from Africa, and has been proposed as a potential treatment for substance use disorders. In animal models, ibogaine reduces ethanol self-administration. However, no study to date ha...

Effect of Voacamine upon inhibition of hypoxia induced fatty acid synthesis in a rat model of methyln-nitrosourea induced mammary gland carcinoma.

Singh, Singh, Rastogi et al.· BMC Mol Cell Biol· 2021· PMID: 34090331
Preclinical (Animal)

In the present study, fatty acid synthesis is targeted to combat mammary gland carcinoma by activating prolyl hydroxylase-2 with Voacamine alone and in combination with Tamoxifen. It was hypothesized that the activation of prolyl hydroxylase-2 would inhibit the hypoxia-induced fa...

The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Iyer, Favela, Zhang et al.· Nat Prod Rep· 2021· PMID: 32794540
Review

Covering: 2000 up to 2020 Few classes of natural products have inspired as many chemists and biologists as have the iboga alkaloids. This family of monoterpenoid indole alkaloids includes the anti-addictive compound ibogaine as well as catharanthine, a precursor to the chemothera...

A new approach methodology (NAM) for the prediction of (nor)ibogaine-induced cardiotoxicity in humans.

Shi, Wesseling, Bouwmeester et al.· ALTEX· 2021· PMID: 34271588
Unclassified

The development of non-animal-based new approach methodologies (NAMs) for chemical risk assessment and safety evaluation is urgently needed. The aim of the present study was to investigate the applicability of an in vitro-in silico approach to predict human cardiotoxicity of the ...

Tropane-Based Ibogaine Analog Rescues Folding-Deficient Serotonin and Dopamine Transporters.

Bhat, Guthrie, Kasture et al.· ACS Pharmacol Transl Sci· 2021· PMID: 33860180
Preclinical (Lab)

Missense mutations that give rise to protein misfolding are rare, but collectively, defective protein folding diseases are consequential. Folding deficiencies are amenable to pharmacological correction (pharmacochaperoning), but the underlying mechanisms remain enigmatic. Ibogain...

Ibogaine Has Sex-Specific Plasma Bioavailability, Histopathological and Redox/Antioxidant Effects in Rat Liver and Kidneys: A Study on Females.

Tatalović, Vidonja Uzelac, Mijović et al.· Life (Basel)· 2021· PMID: 35054409
Preclinical (Lab)

Ibogaine induces rapid changes in cellular energetics followed by the elevation of antioxidant activities. As shown earlier in male rats, ibogaine treatment with both 1 and 20 mg/kg b.w. per os led to significant glycogenolytic activity in the liver. In this work, female rats tre...

Registered clinical studies investigating psychedelic drugs for psychiatric disorders.

Siegel, Meshkat, Benitah· Journal of psychiatric research· 2021· PMID: 34048997
Review

Psychedelics are a hallucinogenic class of psychoactive drugs with the primary effect of activating non-ordinary states of consciousness. Due to the positive preliminary findings of these drugs in the treatment of psychiatric disorders, the number of registered clinical studies h...

Death due to consumption of ibogaine: case report.

Aćimović, Atanasijević, Denić· Forensic science, medicine, and pathology· 2021· PMID: 33433774
Case Report

Ibogaine is a psychotropic indole alkaloid extracted from the roots of the Tabernanthe iboga shrub from the Apocynaceae family. Depending on the taken dose, it can lead to stimulant effects, euphoria, visual and auditory hallucinations, along with auditory, olfactory, and gustato...

Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse.

Luz, Mash· Expert opinion on drug metabolism & toxicology· 2021· PMID: 34139922
Preclinical (Animal)

A non-hallucinogenic psychedelic analogue with therapeutic potential.

Cameron, Tombari, Lu· Nature· 2021· PMID: 33299186
Preclinical (Animal)

The psychedelic alkaloid ibogaine has anti-addictive properties in both humans and animals1. Unlike most medications for the treatment of substance use disorders, anecdotal reports suggest that ibogaine has the potential to treat addiction to various substances, including opiates...

Anticancer activity of Voacangine against human oral cancer cells is due to G2/M cell cycle arrest, ROS-mediated cell death and inhibition of PI3K/AKT signalling pathway.

Xiao, Hou, Fang et al.· J BUON· 2020· PMID: 33099948
Unclassified

Oral cancer is the 6th most prevalent type of cancer and is responsible for high human morbidity and mortality. The present study was designed to investigate the anticancer effects of Voacangine against human oral cancer and to decipher the underlying molecular mechanisms respons...

Quantitative Evaluation of a Mexican and a Ghanaian Tabernaemontana Species as Alternatives to Voacanga africana for the Production of Antiaddictive Ibogan Type Alkaloids.

Krengel, Dickinson, Jenks et al.· Chem Biodivers· 2020· PMID: 32232967
Preclinical (Lab)

In continuation of our efforts to provide quantitative information on antiaddictive ibogan type alkaloid-producing Tabernaemontana species, we used gas chromatography-mass spectrometry (GC/MS) to compare the alkaloid profiles of the barks and/or leaves of one Mexican and one Afri...

Voacamine: Alkaloid with its essential dimeric units to reverse tumor multidrug resistance.

Condello, Pellegrini, Multari et al.· Toxicol In Vitro· 2020· PMID: 32135239
Unclassified

Search for natural substances in association with conventional chemotherapeutic drugs with a chemiosensitizing action easily accessible to the tumor mass has encouraged our studies on voacamine (VOA) and its monomeric units, voacangine and vobasine. Our previous results showed th...

Natural product research

Garcellano, Cort, Moinuddin et al.· Nat Prod Res· 2020· PMID: 30773907
Preclinical (Lab)

Coronaridine (1) was isolated from the CH2Cl2 root extract of Tabernaemontana ternifolia. The structure of 1 was established from 1D- and 2D-NMR and HR-ESIMS experiments, and by comparison with reported spectroscopic data. To date, this is the first report of compound 1 from T. t...

Identification and Validation of VEGFR2 Kinase as a Target of Voacangine by a Systematic Combination of DARTS and MSI.

Kim, Sugihara, Kim et al.· Biomolecules· 2020· PMID: 32230857
Preclinical (Animal)

Although natural products are an important source of drugs and drug leads, identification and validation of their target proteins have proven difficult. Here, we report the development of a systematic strategy for target identification and validation employing drug affinity respo...

← PrevPage 4 / 14Next →